Ongoing studies are evaluating lower-intensity therapy (HMA + venetoclax) combined with ponatinib for patients with Ph + myeloid malignancies, including CML-MBP (NCT04188405), which may further improve outcomes for this disease. The gene discussed is MBP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.